As a result, the discovery that PDCD1 is a common hub gene with druggable potential provides a rationale for clinical studies exploring combination therapies that include both BTK inhibitors and immune checkpoint inhibitors in CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.